Press ReleasesMediaPublicationsOctober 25, 2022Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunityScience Immunology 7: 76Simone A. Minnie, Olivia G. Waltner, Kathleen S. Ensbey, Nicole S. Nemychenkov, Christine R. Schmidt, Shruti S. Bhise, Samuel R. W. Legg, Gabriela Campoy, Luke D. Samson, Rachel D. Kuns, Ting Zhou, John D. Huck, Slavica Vuckovic2 Danniel Zamora, Albert Yeh, Andrew Spencer, Motoko Koyama, Kate A. Markey, Steven W. Lane, Michael Boeckh, Aaron M. Ring, Scott N. Furlan, Geoffrey R. HillJune 24, 2020IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapyNature 583, 609–614Ting Zhou, William Damsky, Orr-El Weizman, Meaghan K. McGeary, K. Patricia Hartmann, Connor E. Rosen, Suzanne Fischer, Ruaidhri Jackson, Richard A. Flavell, Jun Wang, Miguel F. Sanmamed, Marcus W. Bosenberg & Aaron M. RingApril 5, 2023Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid TumorsAugust 16, 2022Simcha Therapeutics Accelerates Growth with Key Leadership Appointments, Expanded Research and Option Agreement with Yale School of MedicineJanuary 27, 2022Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1/2 Study to Evaluate Novel Interleukin-18 Variant in CancerJune 24, 2020Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune SystemDecember 7, 2022ASH22 could be IL-18’s watershed momentJanuary 27, 2022Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raiseJune 24, 2020Engineering a better immunotherapy to outwit cancer — and launch a biotechJune 24, 2020Simcha debuts with $25M to advance custom-built IL-18 for cancer